Wolff, N C <br/><br/>
Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.  [electronic resource] 

 -  Blood  Nov 2001 
 - 2808-16 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Standard No.: </label>10.1182/blood.v98.9.2808  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Benzamides<br/>Bone Marrow Cells--metabolism<br/>Bone Marrow Transplantation<br/>DNA-Binding Proteins--drug effects<br/>Disease Models, Animal<br/>Fusion Proteins, bcr-abl--genetics<br/>Imatinib Mesylate<br/>Immediate-Early Proteins--genetics<br/>Leukemia, Experimental--drug therapy<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Leukocyte Count<br/>Mice<br/>Mice, Inbred BALB C<br/>Milk Proteins<br/>Piperazines--administration & dosage<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyrimidines--administration & dosage<br/>RNA, Messenger--metabolism<br/>Retroviridae--genetics<br/>STAT5 Transcription Factor<br/>Spleen--metabolism<br/>Suppressor of Cytokine Signaling Proteins<br/>Survival Rate<br/>Trans-Activators--drug effects<br/>Transduction, Genetic